Search
forLearn
5 / 801 resultsResearch
5 / 1000+ resultsresearch 40062 Mini pulse corticosteroid therapy with oral dexamethasone for moderate to severe alopecia areata: a multicentric study
Mini pulse corticosteroid therapy with oral dexamethasone is effective and has fewer side effects for treating extensive alopecia areata.
research Treatment of Alopecia Areata and Its Numerous Possibilities: A Literature Review
Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.
research Comparison of resumption of ovulation after cessation of oral contraceptives and medroxyprogesterone acetate in women with polycystic ovary syndrome
Medroxyprogesterone acetate is as effective as oral contraceptives for resuming ovulation in women with PCOS.
research Genetic Defects in Human Pericentrin Are Associated With Severe Insulin Resistance and Diabetes
People with PCNT mutations often develop severe insulin resistance and early-onset diabetes during childhood or adolescence.
research POINT OF CARE W RADIOLOGII
Point of Care in radiology speeds up diagnosis and treatment by performing tests where the patient is.
Community Join
5 / 1000+ resultscommunity PTD-DBM Update: Q&A With Dr. Kang-Yell Choi
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
community New company created by Dr. Kang-Yell Choi to commercialize PTD-DBM therapy
PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.
community Micro needling and ptd-dbm progress
The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community The lowest cyproterone dose to stop mpb
The conversation discusses using cyproterone acetate at 12.5 mg to manage hair loss, with concerns about its effects on testosterone and potential health issues. Other treatments mentioned include finasteride, dutasteride, minoxidil, and RU58841, with varying experiences and outcomes.